The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)

NCT00292877 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Asthma

Interventions

DRUG: SB-240563 (Mepolizumab)

Sponsor

St. Joseph's Healthcare Hamilton

Collaborators

[object Object]